Comparative Pharmacology
Head-to-head clinical analysis: BAL versus CALCIUM DISODIUM VERSENATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus CALCIUM DISODIUM VERSENATE.
BAL vs CALCIUM DISODIUM VERSENATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."